Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Tamoxifen may help treat mania in patients with bipolar disorder

A small, three-week trial of tamoxifen, a drug typically used to treat breast cancer, indicates that it also may decrease symptoms of mania in patients with bipolar disorder, according to a report in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Mar 2008

Depression in seniors

Depression is sometimes viewed as a normal part of aging.

13 Feb 2008

Scientists identify protein's crucial role in resistance to breast cancer treatment

Scientists at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research in London have identified how some breast cancers may become resistant to hormone treatments like tamoxifen.

4 Feb 2008

Breakthrough in breast cancer treatment

Researchers at the Tenovus Centre for Cancer Research at Cardiff University have made a breakthrough in breast cancer treatment that could help save the lives of women who become resistant to breast cancer drugs such as tamoxifen.

21 Jan 2008

Chemotherapy and tamoxifen reduce risk of second breast cancer

Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.

28 Dec 2007

Effectiveness and risks of six bisphosphonates for osteoporosis

Many medications reduce the risk of bone fractures in people with osteoporosis, but the most commonly used drugs - bisphosphonates - have not been proven more effective than alternatives, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services.

18 Dec 2007

Do people make better decisions when they understand average risk?

If there were a pill that would cut your risk of breast cancer in half, would you take it" What if you were told your risk of breast cancer was already below average"

14 Dec 2007

High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer

High-dose chemotherapy and autologous stem cell transplantation, the controversial, arduous, yet once-popular combination treatment that fell out of favor as a therapy for breast cancer, has proven not to be beneficial as an adjuvant therapy for women with node-positive disease, according to an expansive analysis conducted by researchers at The University of Texas M. D. Anderson Cancer Center.

14 Dec 2007

Early results show promise in reducing side effects from anastrozole

A common osteoporosis drug can shield women against the loss of bone mineral density - a side effect of the drug anastrozole which is taken to prevent breast cancer in the IBIS-2 study - according to new data presented at the San Antonio Breast Cancer Symposium.

14 Dec 2007

Novel technique using computer modeling identifies potential side effects of pharmaceuticals

Early identification of adverse effects of drugs before they are tested in humans is crucial in developing new therapeutics, as unexpected effects account for a third of all drug failures during the development process.

12 Dec 2007

Study shows how mutations in the BRCA1 gene lead to breast cancer

An international team of researchers led by Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center and Sweden's Lund University has, for the first time, revealed how mutations in the BRCA1 gene lead to breast cancer.

10 Dec 2007

AstraZeneca receives six months pediatric exclusivity patent extension for ARIMIDEX (anastrozole)

AstraZeneca has announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX (anastrozole) for its licensed breast cancer indications until June 2010.

2 Dec 2007

New computational technique predicts side-effects of a major cancer drug

Researchers at the University of California San Diego have developed a novel computer technique to search for the side effects of major pharmaceuticals.

29 Nov 2007

HER-2 status predicts success of chemotherapy in breast cancer treatment

Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.

10 Oct 2007

African-American women less likely to have adjuvant cancer therapy than white women

A new study finds that white women more frequently take more of the life-prolonging supplemental therapies used to treat breast cancer than African-American women.

9 Oct 2007

Treatment for breast cancer differs between African-American women and white women

The study found that, among patients with breast cancer that had spread to the lymph nodes, African-Americans were less likely to have adjuvant cancer therapy than white women. In this clinical group, white women were almost five times more likely to take Tamoxifen, a widely-used cancer therapy medication, and over three times more likely to have chemotherapy.

9 Oct 2007

Causes and treatments for gynecomastia

Gynecomastia, the benign enlargement of male breast tissue, is a common occurrence in adolescents as well as in middle-aged and older men.

20 Sep 2007

Risedronate prevents bone loss after breast cancer treatment

Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research.

18 Sep 2007

TFAP2C gene may be useful target for new breast cancer therapies

University of Iowa researchers have discovered a gene that plays a linchpin role in the ability of breast cancer cells to respond to estrogen.

17 Sep 2007

Evista (raloxifene hydrochloride) approved for breast cancer

The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

17 Sep 2007